This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OXFD Oxford Immunotec Global (OXFD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Oxford Immunotec Global Stock (NASDAQ:OXFD) 30 days 90 days 365 days Advanced Chart Get OXFD alerts:Sign Up Key Stats Today's Range$21.99▼$21.9950-Day Range$21.88▼$21.9952-Week Range$8.37▼$23.11VolumeN/AAverage Volume1.10 million shsMarket Capitalization$570.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Read More… Receive OXFD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter. Email Address OXFD Stock News HeadlinesOxford researchers develop new method of identifying fake Covid-19 vaccinesFebruary 3, 2025 | msn.comA Game-Changing VaccineOctober 30, 2024 | time.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.June 2, 2025 | Paradigm Press (Ad)Oxford Farming Conference announces 2025 Inspire DelegatesOctober 18, 2024 | msn.comNigeria rolls out new Oxford R21 malaria vaccineOctober 18, 2024 | reuters.comUniversity of Oxford scientist addresses UN on tackling antimicrobial resistanceOctober 1, 2024 | msn.comTuberculosis Diagnostics Test Market to hit USD 3.7 billion by 2032, says Global Market Insights Inc.September 24, 2024 | finance.yahoo.comBoat Race: Oxford rowers criticise sewage levels in River ThamesSeptember 16, 2024 | bbc.co.ukSee More Headlines OXFD Stock Analysis - Frequently Asked Questions How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). The business had revenue of $19.44 million for the quarter, compared to the consensus estimate of $18.58 million. Oxford Immunotec Global had a negative trailing twelve-month return on equity of 8.39% and a negative net margin of 30.51%. What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Immunotec Global investors own include Intel (INTC), Gilead Sciences (GILD), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Gold Resource (GORO). Company Calendar Last Earnings11/03/2020Today6/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:OXFD CIK1586049 Webwww.oxfordimmunotec.com Phone44-0-12-3544-2780FaxN/AEmployees273Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.81 million Net Margins-30.51% Pretax MarginN/A Return on Equity-8.39% Return on Assets-7.63% Debt Debt-to-Equity RatioN/A Current Ratio15.96 Quick Ratio14.85 Sales & Book Value Annual Sales$73.71 million Price / Sales7.75 Cash Flow$0.02 per share Price / Cash Flow1,408.78 Book Value$8.08 per share Price / Book2.72Miscellaneous Outstanding Shares25,962,000Free FloatN/AMarket Cap$570.90 million OptionableNot Optionable Beta1.42 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:OXFD) was last updated on 6/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Gold analyst, Sean Brodrick, gave everyday investors an advance notice of this historic surge. When the bul...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Immunotec Global PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Immunotec Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.